bluuebunny/crossref_metadata_2025_split huggingface dataset:
Randomized multicenter phase II trial of navcap (vinorelbine and capecitabine) versus navcap followed by weekly docetaxel as first line treatment in HER-2/neu negative metastatic breast cancer patients: updated results.
Authors: Ghosn M , Farhat FS , Kattan JG , Hanna C , Younes F , Haddad N , Aftimos P , Nasr F , Moukaddem W , Chahine G 
Published: December 2010

Abstract
Abstract #6116
Background: Capecitabine (C), vinorelbine (V) and docetaxel (D) are effective in the 1st line treatment of metastatic breast cancer (MBC). Based on the efficacy and the tolerability of Navcap (M. Ghosn et al. Antican Res 2006) and Navcap followed by docetaxel in MBC (M. Ghosn et al. Can Chemother Pharmacol 2008), we initiated a randomized phase II study. Primary Objective: To compare the objective response rate (ORR) of 8 cycles of Navcap vs. 4 cycles of Navcap followed by 12 weekly Docetaxel in the 1st line setting of MBC. Methods: Patients (pts) with measurable disease, no prior chemotherapy in MBC and Her-2/neu negative are eligible. All pts will receive Navcap (V 25 mg/m2 on d1 & d8 as IV push and C 825 mg/m2 bid D1-14 q3w) for 4 cycles. Pts progressing under treatment with Navcap are withdrawn and receive Docetaxel as 2nd line treatment. Pts responding or stable after completing 4 cycles of Navcap are randomized to: Arm A (4 Navcap) or Arm B (12 weekly Docetaxel 25 mg/m²/week). Results: From July 2004 to June 2008, a total of 110 pts were enrolled. At the time of this analysis 78 pts had completed the first 4 cycles of Navcap with an ORR of 55% (CR 13%) and a stable disease of 19%. 20 pts (26%) were excluded from randomization due to PD. 58 pts were randomized: Arm A: 30 pts and Arm B: 28 pts. Patient characteristics are summarized in table 1. All pts were evaluable for response with objective response rates of 70% & 78% in Arms A and B respectively. The median TTP & overall survival are 10 & 34 months in Arm A; 11 & 34 months in Arm B. Statistical comparison for efficacy & survival outcomes will be done once all pts are randomized & long term follow-up is available. All pts were evaluable for toxicity. The majority of adverse events were mild. Arm A: Gr 4 neutropenia (3%), Gr 3 anemia (6%). Arm B: Gr 3-4 anemia (9.6%), Gr 3 leukopenia (4.8%) & Gr 2 alopecia (14.3%). Conclusions: These preliminary results show that Navcap confirms its high response rate in 1st line treatment for HER-2/neu negative MBC. By the date of the meeting all pts will be randomized and will have completed their treatment. Mature data will be presented accordingly. (Protocol initiated & coordinated by the Cancer Research Group/Collaborative Group, Beirut–Lebanon).&#x2028; &#x2028;
Citation Information: Cancer Res 2009;69(2 Suppl):Abstract nr 6116.
A multicenter phase II trial of weekly paclitaxel (wPC) and epirubicin (E) in first line metastatic breast cancer (MBC) and pronostic impact of VEGF level.
Authors: Abadie S , Capitain O , Delva R , Maillart P , Soulié P , Bourbouloux E , Levy C , Delozier T , Campone M , Morin Meschin M , Delecroix V , Ollivier J , Boux de Casson F , Poirier A , Berger V , Fumoleau P , Gamelin E 
Published: December 2010

Abstract
Abstract #6122
Background : wPC and E are effective in the treatment of MBC. The main objective was to determine the efficacy of combined induction with wPC and E followed by consolidation with wPC. Secondary objective were to determine tolerance survivals and characterize antiangiogenic PC activity and predictive values of plasmatic neurotrophic and endothelial factors, in terms of neurotoxicity and efficacy.&#x2028; Methods : patients (pts) with RECIST measurable metastasis were recruited from april 2004 to may 2006 : ages (18-75 y) PS≤2, prior neoadjuvant adjuvant chemotherapy (NA-A CT) was permited if &gt;6 month. 3 cycles [wPC 80 mg/m² (D1, D8, D15, reinduction D28) and epirubicine 100 mg/m² D15], were followed by wPC (no week rest). VEGF, IL6, IL6SR, BDNF were measured in plasma at baseline and C2. Evaluation was performed after 3 induction cycles and every 3 month. A Simon optimal two-stage design was performed with 13 objective responses, allowing to accrue 25 more patients (28 responses expected).&#x2028; Results : 54 patients: median age 58.5 (30-75); 81% had surgery, 53.7% radiotherapy and 40.7% had NA-A CT, 46.3% hormonotherapy. Metastatic sites were nodes (36) lung (36) liver (28) bone (23). 100% PC and 90% E dose were administered at C2 and C3. 49 patients were evaluable for response; 3 patients withdrawn for taxol hypersensitivity, 1 early death (GIII asthenia and dyspnea), 1 investigator's decision. ITT analysis was performed: 33 responses (ORR: 61 %) Median OS was 30 months. During induction, 16 grade III, 27 grade IV and 3 febrile neutropenia were reported. There were 13 serious adverse events.&#x2028; Consolidation was mainly associated with neurotoxicity n=28 (20pts), GIII (n=1; 3.6%) GIV (n=1; 3.6%), astenia n=26 (18pts) ), GIII n=1; 3.8% GIV n=1; 3.8%and onycholysis n=15 (13pts) ), GIII n=2 ; 13.4% GIV n=1; 6.7%.&#x2028; High initial VEGF plasma levels were correlated with poor survival s (PFS, OS) with an univariate cox model (OR=1.954, 95%CI 0.944-4.043, p=0.071 ; HR 4.437, 95%CI 1.731-11.371, p=0.0019). Thresholds were determined. No correlation were observed between neurotoxicity and IL6, IL6SR and BDNF plasma levels.&#x2028; Conclusion : Despite the significant but manageable haematologic toxicity, PC + E showed a high efficacy. VEGF plasma levels are predictive of the outcome and should be tested as antiangiogenic drugs targeting factors.This work was supported in part by BMS.
Citation Information: Cancer Res 2009;69(2 Suppl):Abstract nr 6122.
A dose-finding and pharmacokinetic study of I.V. vinflunine in combination with doxorubicin as first line treatment of metastatic breast cancer.
Authors: Machiels J , Chollet P , Taleb A , Baurain J , Humblet Y , Mazzeo F , Zaman K , Kasiborski F , Bauer J 
Published: December 2010

Abstract
Abstract #6124
Background: VFL is a novel bifluorinated tubulin-targeted agent of the vinca alkaloids class. In a phase II study in anthracycline and taxane pretreated MBC patients (pts), an ORR of 30% observed. Given activity shown by DXR or VFL in MBC, we conducted a phase I study of the combination, define maximum tolerated dose (MTD), recommended dose (RD), safety (NCI CTC 2.0), PK interaction and efficacy (Recist).&#x2028; Methods: 2 schedules investigated (VFL D1 with DXR D1, every 3 weeks and VFL Ds 1 and 8, with DXR Ds 1 and 8, every 3 weeks). Eligibility: Pts with MBC, previously untreated for metastatic disease; could have received adj/neoadjuvant with anthracycline-containing regimen, cumulative doses &lt; 250 mg/m² for DXR, 450 mg/m² for EPI. Dose escalation used 3+3 design; PK samples were obtained for VFL and DXR to investigate potential interaction.&#x2028; &#x2028; Results: 32 patients were enrolled (15 patients in schedule 1 and 17 in schedule 2) and received escalating doses of VFL and DXR.&#x2028; In schedule 1, 2 dose levels (DL) were investigated; At DL VFL250/DXR50, 8 pts were treated with 6 patients evaluable for DLT, where 2 DLTs were identified consisting of neutropenia &lt; 0.1x109/l &gt; 3 days and a neutropenic infection; then this DL was considered MTD; at the DL VFL250/DXR40, 7 pts were treated without developing DLTs then considered RD. 73 cycles were administered (median 6); Most frequent haematological toxicity was neutropenia, gr 3 in 1 pt and gr 4 in 11 pts. Main non-haematological adverse events were: nausea 80%, fatigue 73.3%, constipation 40%, vomiting 40%, anorexia 33.3%, stomatitis 20%, dyspnea 13.3%. Clinical activity: 7 pts (46.7%) had PR, and 4 pts (26.7%) SD. No PK interaction was detected.&#x2028; In schedule 2, at DL VFL150/DXR25, 6 of 9 pts were evaluable in whom 2 Gr 4 neutropenia &gt; 7 days occurred, (DL considered as MTD). In the DL below VFL120/DXR25, 6 of 8 pts were evaluable, only 1 Gr 4 neutropenia &gt; 7 days occurred, (DL considered RD). A total of 89 cycles (median 6) were administered; neutropenia was the main haematological toxicity, with Gr ¾ in 14 pts (82.4%); main non-haematological toxicities: fatigue 82.4%, constipation 76.5%, nausea 76.5%, vomiting 64.7%, stomatitis 41.2%, dyspnea 41.2%, anorexia 35.3%; no episode of Gr 4 occurred.&#x2028; Among 17 treated pts, 8 (47.1%) had PR and 6 (35.3%) SD. PK analysis ongoing.&#x2028; Conclusion: RD for schedule 1 is VFL250/DXR40 on day 1, Q3W, for schedule 2, VFL120/DXR25 on days 1 and 8, Q3W. Overall VFL/DXR combination is feasible and toxicity was manageable, where haematological toxicity was frequent but reversible. Promising antitumour activity was detected.
Citation Information: Cancer Res 2009;69(2 Suppl):Abstract nr 6124.
Optimal treatment and prognosis of breast cancer after Hodgkin's disease: analysis of 143 cases.
Authors: Cutuli B , Tunon de Lara C , Livi L , Baron M , Levy C , Kerbrat P , Provencio M , Gonzague-Casabianca L , Mege A , Lemanski C , Delva C 
Published: December 2010

Abstract
Abstract #6153
Background &#x2028; Breast cancer (BC) is the most frequent second malignancy in women treated for Hodgkin's disease (HD), but there are few specific data on these tumors. This study assesses histopathological features, locoregional and systemic treatments as well as prognostic factors of these secondary BC.&#x2028; Material and methods:&#x2028; 127 women treated for HD in 9 centers subsequently developed 143 BC. Median age at HD diagnosis was 25 years. HD stages were I, II, III and IV in 28%, 49%, 16% and 7%. Radiotherapy (RT) alone was used in 44 cases and chemotherapy (CT) + RT in 83 cases. Twelve patients relapsed and had a new treatment by RT (3), CT (5) or both (4).&#x2028; Results:&#x2028; First BC occurred after 18-year median interval (&lt;10 years: 11%; 10-20 years: 49%; &gt;20 years: 40%). TNM classification (126/143) showed 23 mammographically detected T0 (18%), 54 T1 (43%, 40 T2 (32%) and 9 T3T4 (7%). 129 tumors were infiltrating carcinoma (IC) and 14 (10%) DCIS. Twenty-four (17%) tumors were multifocal. Five patients had metastasis at diagnosis; 135 tumors were operated (121 IC and 14 DCIS): 57 (42%) by conservative surgery (40 with RT) and 78 (58%) by mastectomy (5 with RT). Axillary dissection (AD) and SNB were performed in 74% and 23% of the cases. Median tumor size for IC was 19 mm. Axillary nodal involvement (ANI) was found in 28% of IC (pN1-3 : 22%; pN&gt;3 : 6%). ER and PgR were positive in 57% and 49%.&#x2028; 43 (39%) tumors were SBR III (high grade). Chemotherapy (CT) and hormonotherapy (HT) were performed in 47% and 42% of IC. With a 5-year median FU, 17 patients (12%) developed local recurrences (LR) and 35 (30%) had metastases. Significant metastasis predictive factors were ANI and SBR III; 12 (10%) women developed a third cancer.&#x2028; 5 and 10-year overall survival (OS) rates were 69% and 53%, and disease-specific survival (DSS) rates 72% and 62%. 5-year DSS rates were 79% for T0T1 versus 44% for pT2T3T4 (p=0.0068) and 81% for pN0 versus 65% for pN+ (p=0.0012).&#x2028; Conclusion&#x2028; Young women (especially 15-25 years) treated for HD should be carefully monitored by mammography, ultrasound and maybe MRI in order to detect early occurrence of BC. The prognosis of small lesions (pTis/pT1) is excellent and conservative treatment often feasible. This study is still ongoing, with 200 planned cases. Optimal adjuvant treatment options will be discussed and compared with a former series including 133 cases (Radiotherapy and Oncology, 2001, 59: 247-255).
Citation Information: Cancer Res 2009;69(2 Suppl):Abstract nr 6153.
Effect of tibolone on breast cancer recurrence: LIBERATE trial bone sub-study.
Authors: Bundred NJ , Kenemans P , Beckmann MW , Foidart J , Kubista E , von Schoultz B , Sismondi P , Vassilopoulou-Sellin R , Yip C , Egberts J , Planellas Gomez JV , el Galta R , van Os SC 
Published: December 2010

Abstract
Abstract #66
LIBERATE, a randomized, placebo controlled, double blind trial studied the effect of tibolone (Livial), a tissue selective hormone replacement therapy (HRT) on breast cancer (BC) recurrence, aiming to demonstrate non-inferiority of treatment compared to placebo. In the LIFT trial of osteoporotic women, tibolone prevented BC development.&#x2028; Design and Method: Women with surgically treated BC (T1-3, N0-2, M0) within the last 5 years complaining of vasomotor symptoms, were randomly assigned to tibolone 2.5mg daily or placebo treatment for a maximum of 5 years. Adequate sample size was estimated to be &gt;1500 in each arm. A bone mineral density (BMD) sub-study of 724 patients (454 Caucasian; 270 Asian) was enrolled utilizing DXA scanning at baseline and 2 years.&#x2028; Results: Between 2002 and 2004, 3,148 women were randomized in 31 countries; 1579 to tibolone and 1569 to placebo. Mean age at randomization was 52.7 years (28.0-75.0) and mean time since surgery was 2.1 years. In total 58% of women recruited were node positive and 78% ER positive. The trial closed prematurely in July 2007, with a median follow-up of 3.1 years (0.01-4.99) per patient, because an increased risk of BC recurrence occurred on tibolone HR 1.40 (1.14-1.70; p&lt;0.001); 15.2% (237/1556) women on tibolone recurred compared to 10.7% (165/1542) on placebo. Risk for distant recurrence on tibolone was HR 1.38 (95% CI 1.09-1.74 p=0.007).&#x2028; Aromatase inhibitor (AI) users had the highest risk of recurrence on tibolone HR 2.42 (1.01-5.79) compared to tamoxifen treated women HR 1.25 (0.98-1.59). Compared to ER positive cancers HR 1.56 (1.22-2.01), ER negative cancer had no increased risk of recurrence HR 1.15 (0.73-1.80). No differences in mortality occurred between groups.&#x2028; At entry to the bone sub-study, 298 (43%) women had normal BMD, 313 (45%) osteopenia (T-score between -1 and -2.5) and 81 (11.7%) osteoporosis. Low body mass index (&lt;0.001), Asian race (p&lt;0.001) and old age at menarche predicted for low bone mass after 2 years. Tibolone increased BMD by 3.5% at the lumbar spine and 2.9% at the hip compared to placebo (both p&lt;0.001) and reduced fracture rate in the Caucasian (p=0.036) but not the Asian population. Women with normal BMD (before or at day 1) had increased recurrence on tibolone 15.1% (21/139) compared to placebo 6.9% (11/159) p=0.036, whereas no increased BC recurrence was seen in women with low BMD; 7.5% (15/201) on tibolone and 6.7% (13/193) on placebo.&#x2028; Conclusion: HRT after breast cancer treatment increases BC recurrence especially in AI treated patients. Risk of BC recurrence is elevated in BC women with normal BMD (compared to low) who take HRT.
Citation Information: Cancer Res 2009;69(2 Suppl):Abstract nr 66.
Local-regional recurrence with and without radiation after neoadjuvant chemotherapy and mastectomy for T3N0 breast cancer patients.
Authors: Nagar H , Mittendorf EA , Strom EA , Perkins G , Oh JL , Tereffe W , Woodward W , Gonzalez-Angulo A , Hunt K , Buchholz T , Yu T 
Published: December 2010

Abstract
Abstract #74
Purpose: The goal of this study was to compare the local-regional recurrence (LRR) risk in patients with clinical T3N0 breast cancer who were treated with neoadjuvant chemotherapy (NeoChemo) and mastectomy (Mastx) according to the use of adjuvant radiation (RT).&#x2028; Methods: Clinicopathologic data from 164 patients with clinical T3N0 breast cancer who received NeoChemo and Mastx from 1985 to 2004 were retrospectively reviewed. In this cohort, 121 (74%) patients received adjuvant radiation (RT) while 43 (26%) patients did not. The median number of axillary lymph nodes (LN) dissected was 15. After NeoChemo, 54% of patients (n=89) had no pathologically involved lymph nodes at the time of surgery (ypLN-) while 46% (n=75) had at least 1 lymph node pathologically positive (ypLN+). Actuarial rates were calculated using Kaplan-Meier analysis and compared using log-rank test. Cox proportional hazards models were fit to determine the association of RT with the risk of LRR after adjustment for other patient and disease characteristics.&#x2028; Results: At a median follow-up of 77 months, 17 of the 164 patients had a LRR. For all patients, the 5-year local-regional control rates (5-yr LRC) were 90%. The 5-yr LRC for those who received RT (n=121) was 95% and for those who did not received RT (n=43) was 76% (p = 0.002), with a higher proportion of the patients who received RT having pathologically involved LN (+RT 53% vs –RT 23%, p=0.002).&#x2028; Among the entire cohort, the 5-yr LRC was 85% for patients with ypLN+ disease and 94% for patients with ypLN- disease (p=0.093). In patients with ypLN+, the 5-yr LRC with no RT (n=11) was 47% and with RT (n=64) was 92% (p&lt;0.001). In patients with ypLN-, the 5-yr LRC with no RT (n=32) was 86% and with RT (n=57) was 98% (p=0.063). Patients who had tumors with high nuclear grade had worse 5-yr LRC (Grade low 100%, intermediate 97%, high 81%, p=0.023). The presence of lymphovascular invasion, close/positive margin, or estrogen receptor status did not statistically correlate with LRC. In a Cox regression model, patients with tumor exhibiting high nuclear grade (Hazard Ratio (HR) 5.0, 95% Confidence Interval (CI) 1.6-15.4), ypLN+ (HR 6.6, 95% CI 2.0-22.1) and no adjuvant RT (HR 7.6, 95% CI 2.4-24.0) had increased risk of LRR.&#x2028; Conclusions: Post mastectomy adjuvant RT appears to improve LRC in clinical T3N0 breast cancer patients treated with neoadjuvant chemotherapy and mastectomy.
Citation Information: Cancer Res 2009;69(2 Suppl):Abstract nr 74.
Pegylated liposomal doxorubicin (PLD) plus docetaxel significantly improves time to progression (TTP) compared with docetaxel (D) monotherapy in patients with advanced breast cancer (ABC) treated with adjuvant anthracycline: results from a randomized phase 3 study.
Authors: Sparano J , Makhson A , Semiglazov V , Tjulandin S , Balashova O , Bondarenko I , Bogdanova N , Chatikhine V , Zhuang S , Xiu L , Yuan Z , Rackoff W 
Published: December 2010

Abstract
Abstract #80
Background: Earlier studies have showed that PLD (DOXIL®/CAELYX®) has comparable efficacy but is significantly less cardiotoxic than conventional doxorubicin for the treatment of ABC. We sought to determine whether women with ABC who had relapsed at least 1 year after prior adjuvant anthracycline would derive clinical benefit from the addition of PLD to D without an increase in cardiac toxicity.&#x2028; Methods: 751 pts were randomly assigned to receive either D 75 mg/m2 (N=373) or PLD 30 mg/m2 followed by D 60 mg/m2 (N=378) on Day 1 every 21 days. Treatment was to continue until disease progression or the occurrence of unacceptable toxicity. The primary endpoint was TTP and secondary endpoints were overall survival (OS), objective response rate (ORR), cardiac and overall safety. The analysis for TTP was planned after approximately 485 events and for final OS after 485 deaths.&#x2028; Results: This prespecified TTP analysis was performed after 555 TTP events. Median TTP was increased from 7.0 months for D, to 9.8 months for the PLD+D (HR=0.65; 95% CI 1.41, 2.35; P=0.000001), and the ORR was also significantly improved for the PLD+D (26% vs. 35% P=0.0085). OS was similar between the two arms at the time of this interim analysis with 374 (50%) total deaths (HR=1.06; 95% CI 0.86;1.30). Both groups received a median of 6 cycles. Grade 3/4 neutropenia was reported in 66% and 65% of pts on PLD+D arm and D arm, respectively; the incidence of pts with febrile neutropenia was 7% and 6%, respectively, and the overall incidence of pts with grade 3-4 drug-related adverse events was 74% and 66%, respectively. There was no increase in cardiac toxicity, as determined by reported cardiac adverse events or LVEF measurements in the PLD+D arm compared with the D arm. Congestive heart failure was reported in 3 (1%) pts in the PLD+D arm and 4 (1%) pts in the D arm. Grade 3/4 hand-foot syndrome (HFS) and stomatitis were reported for 24% and 11% of PLD+D pts and infrequently in the D group (1% and 1%, respectively).&#x2028; Discussion: Treatment with PLD+D combination results in statistically significant improvement of TTP and ORR compared with D among pts with ABC without an increased risk of cardiac toxicity. Additional follow-up is needed to determine the impact of the combination on OS. HFS and stomatitis occurred more often in pts treated with PLD+D therapy. The addition of PLD to a D-based regimen is a safe and effective option for pts with ABC previously treated with adjuvant anthracycline regimens.
Citation Information: Cancer Res 2009;69(2 Suppl):Abstract nr 80.
A phase I study of vandetanib and metronomic chemotherapy in advanced breast cancer.
Authors: Mayer EL , Isakoff SJ , Hannagan K , Savoie J , Beckman J , Klement G , Gelman R , Winer EP , Burstein HJ 
Published: December 2010

Abstract
Abstract #906
Background: Vandetanib (V) is an oral tyrosine kinase inhibitor of vascular endothelial growth factor (VEGF) receptors 2 and 3 and epidermal growth factor receptor. Metronomic chemotherapy, continuous low-dose oral cyclophosphamide and methotrexate (CM), has activity in combination with anti-angiogenic treatments. We sought to define the safety and tolerability of all-oral combination therapy with V and CM in advanced breast cancer.&#x2028; Patients and Methods: Eligible patients (pts) had stage IV breast cancer; measurable disease was not required and stable brain metastases were acceptable. Up to 4 prior chemotherapy regimens were allowable, as was prior bevacizumab. Pts with systemic anticoagulation or QTc abnormalities were excluded. Three sequential dose escalation cohorts of approximately 8 pts were enrolled. All pts received CM (C 50 mg PO qd, M 2.5 mg PO d1-2 q week), and V in 3 dose-escalation cohorts: 100 mg qd (Cohort 1), 200 mg qd (Cohort 2), and 300 mg qd (Cohort 3). Pts received V + CM until progression or unacceptable toxicity; dose adjustments were made for treatment related toxicity. The primary endpoint was safety and toxicity of the regimen; secondary endpoints included response rate, non-invasive vascular analysis of hypertension, and platelet proteomics.&#x2028; Results: 24 pts (median age 49 years) entered the study. 83% had visceral disease, 92% had received prior chemotherapy for metastatic disease (median number of regimens, 2), and 38% had received prior bevacizumab. Median cycles of therapy completed was 2 (range 1-8); median number of weeks on study was 8 (range 2-33). Toxicities in Cohorts 1 and 2 were generally manageable, and most commonly consisted of diarrhea, nausea, fatigue, abnormal hepatic function, and hyperglycemia. Despite fewer cycles of drug exposure, increased toxicity was observed in Cohort 3, including 3 episodes of dose limiting toxicity (mucositis/rash, 1; abnormal hepatic function, 2). One-third of pts required V dose reduction, and 21% of pts came off study for toxicities including cerebrovascular event (1), pulmonary embolus (1), rash (1), abnormal hepatic function (1), and myocarditis (1). Moderate hypertension was observed in 42% of pts, with a single grade 3 event. Of the 20 response-evaluable pts, 2 (10%, 95% CI 1.2 – 31.7 %) demonstrated partial response, one lasting over 30 weeks, and 3 had stable disease &gt; 24 wks (15%, 95% CI 3.2 – 37.9%). Results from correlative vascular hypertension analyses and platelet proteomics will be presented.&#x2028; Conclusions: The all-oral regimen of V + CM was tolerable at a maximum dose of V 200 mg qd. Dose-limiting toxicity was seen in the V 300 mg cohort. Modest clinical activity in this heavily pretreated population was observed, and supports further investigation of this anti-angiogenic regimen in advanced breast cancer.
Citation Information: Cancer Res 2009;69(2 Suppl):Abstract nr 906.